Business Wire

ORIGYN-FOUNDATION

23.11.2021 15:40:13 CET | Business Wire | Press release

Share
ORIGYN Foundation Receives Strategic Investment of $20M from World-Renowned Investors, including Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko and Vectr Ventures

ORIGYN Foundation , the Swiss nonprofit dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has today announced a strategic raise of $20 million. Investors in this round include Bill Ackman’s Table Management, Polychain Capital, Paris Hilton, Coinko, Vectr Ventures, Carter Reum, Div Turakhia, GD10 Ventures and more. Ahead of the foundation’s public token release, this private round now values ORIGYN at $300 million.

“We’re incredibly fortunate and excited to include so many influential names in this funding round. ORIGYN is unique in what it brings to this world. It’s a sign of support for what ORIGYN is trying to achieve—using technology to solve for identity, authenticity and proof of ownership. Our partners have seen the opportunity we provide to unlock value for owners and creators,” said Daniel Haudenschild, CEO of ORIGYN Entreprise SA, which is the operating entity of ORIGYN Foundation.

Founded in October of 2020, ORIGYN is led by its founding partners and council members Gian Bochsler, Vincent Perriard and Mike Schwartz, as well as by CEO Daniel Haudenschild. The foundation’s technology certifies and guarantees the authenticity of physical and digital items using advanced recognition and identification techniques created by leading experts in computer vision, artificial intelligence and decentralized infrastructure. It also unites the greatest contemporary players across select industries to protect, celebrate, elevate and reward creativity through its novel approach to NFTs.

ORIGYN currently operates the following industry verticals:

ORIGYN Art is an exclusive community for the fine art market on the blockchain. This vertical establishes a connection between physical works of art and NFT certificates to create the ultimate marketplace experience for creators, industry professionals, collectors and enthusiasts.

ORIGYN Collectibles is a revolutionary platform designed to empower individuals with shared passions to buy, sell, trade and experience collectors’ items. This vertical rewards and celebrates creativity by tokenizing certificates of ownership that verify the uniqueness and authenticity of physical collectibles.

ORIGYN Digital Media is a comprehensive ecosystem built for media creators of all types to activate their social capital. This vertical provides tooling for all forms of experiential content, artifacts and marketplaces for the world’s most creative icons and their fans.

ORIGYN Luxury is the only digital certification solution guaranteed to prove authenticity using a luxury object’s own biometric features. These digital certificates increase trust between companies and their clients with a paperless solution, guaranteed by ORIGYN, which facilitates the resale of the object. This vertical brings NFTs to life by enabling the object itself to become its own proof of authenticity.

Funding from this round powers the foundation’s mission and contributes to the expansion and continuous improvement of ORIGYN’s verticals as directed by governing token holders. Additionally, it will be used to fund ongoing R&D and onboard the foundation’s growing list of industry partners to the ecosystem.

The ORIGYN authentication platform far surpasses other NFT certification solutions in the market today due to the unique biometric and ownership data included in ORIGYN digital twins, as well as the global guarantee that backs every digital certificate. ORIGYN will officially launch these digital certificates across industry verticals during the first half of 2022. The foundation’s utility token, OGY, will also become publicly tradable in 2022. OGY is necessary to engage with the core services of the platform and is used to create and transact certificates of authenticity.


About the ORIGYN Foundation:

The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. For more information, visit origyn.ch .

ORIGYN Foundation: Website Twitter LinkedIn Facebook Medium

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye